- 2020-11-08
- The Journal of dermatological treatment 33(3)
- C R S Prakoeswa
- L Bonita
- A Karim
- N Herwanto
- M A Umborowati
- T Setyaningrum
- A N Hidayati
- I S Surono
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 30
- Population
- 30 adults with mild and moderate AD
- Methods
- randomized double-blind placebo-controlled trial, microencapsulated probiotic (2 × 10^10 CFU/day) vs placebo (skim milk-Avicel) at an outpatient clinic
- Blinding
- Double-blind
- Duration
- 8 weeks
Introduction
Although the therapeutic effects of probiotics in atopic dermatitis (AD) are known, the limited findings in adults are inconsistent. Lactobacillus plantarum (LP) IS-10506 was found to improve AD symptoms due to its immunomodulatory effects.Objective
To assess the Scoring Atopic Dermatitis Index (SCORAD), the serum immunoglobulin E (IgE), interleukin (IL)-4, interferon-gamma (IFN-γ), forkhead box P3 (Foxp3+), and IL-17 levels in adults with mild and moderate AD after LP IS-10506 supplementation.Methods
A randomized double-blind placebo-controlled trial comparing the microencapsulated probiotic (2 × 1010 CFU/day) and placebo (skim milk-Avicel) was conducted at an outpatient clinic on 30 adults with mild and moderate AD. The patients were divided into 2 groups with 15 patients each: intervention and control.Result
The SCORAD score was significantly lower in the probiotic than the placebo group on the 8th week. The IL-4 and IL-17 levels were significantly lower in the probiotic than the placebo group. The IFN-γ and Foxp3+ levels were significantly higher in the probiotic than the placebo group. However, the IgE levels remained significantly unchanged.Conclusion
The administration of LP IS-10506 is effective for alleviating AD symptoms in adults owing to its immunomodulatory effects.